Phoenix Life
Signs Exclusive
Agreement
with Vanuatu Government for 25-Year
Diabetes Management Program and Global Medical Cannabis Export
License
DENVER, CO and Port
Vila, Vanuatu – June 4, 2019 -- InvestorsHub NewsWire
-- –
Phoenix Life Sciences International Limited (OTC: PLSI) ("Phoenix Life", the
"Company"), an adaptive healthcare solutions company, today
announced that it has signed a binding Memorandum of Understanding
(MOU) between the Company and the Ministry of Health on behalf of
the Government of Vanuatu, located in the South
Pacific. The
MOU includes an exclusive 25-year diabetes management program, the
creation of a national healthcare network, medical cannabis
licensing and approval for Phoenix Life to export
globally,
both medical
products for the targeted treatment of diabetes and generic medical
cannabis products from the Republic of Vanuatu.
With this
agreement, Phoenix Life will work with the Ministry of Health to
establish a National Network of Community Healthcare Clinics and
Dispensing Pharmacies throughout the country to manage the national
Type 2 diabetes epidemic for a minimum of the next 25 years. These
clinics will also provide dispensing of Phoenix Life's diabetes
management product, Phoenix Metabolic, as an alternative to insulin
for the nations forecast more than 50,000 type 2 diabetics and an
expected 50,000 high risk pre-diabetics.
Phoenix Metabolic
uses active ingredients from extracts from the cannabis sativa
plant, combined with bioavailability enhancement ensuring high
levels of efficacy and safety in its use in managing type 2
diabetes and its complications. It is accurately dosed, doctor
prescribed, pharmacy dispensed. By being non-psychoactive, is also
ensures no impairment to the patient.
Phoenix Life is
authorized to conduct screenings throughout the Republic of
Vanuatu, including at Vila Central Hospital, to assess health
conditions such as blood sugar levels, hypertension and overall
wellness, among Ni-Vanuatu citizens. The work done at these
Community Healthcare Clinics and Dispensing Pharmacies and the
Company's screening locations will provide a platform for patient
access.
"This agreement is
one of the core building blocks for our licensing, medical trials
and the deployment of our strategy for launching programs to
improve the treatment of type 2 diabetes and its complications on a
global basis," said Phoenix Life CEO and Founder, Martin Tindall.
"We are thankful for this partnership with the Republic of Vanuatu
and we look forward to creating a long and fruitful working
relationship."
Phoenix Life has
already received an exemption from the Ministry of Health for the
importation of products derived from medical cannabis to treat
diabetes in compliance with the Dangerous Drugs Act for initial
trials. The Company has also been approved to globally export
medical products from Vanuatu for both the targeted diabetes
products and generic medical cannabis products.
Additionally, as
part of the agreement, Phoenix Life plans to develop training
programs to educate medical professionals and support personnel on
the best practices, uses of medical cannabis and improved
management of type 2 diabetes and its complications. These programs
will be created in conjunction with leading universities and
colleges from the United States, Australia, New Zealand and The
Republic of Vanuatu.
Phoenix Life
intends to make this same program available to Governments and
their health agencies throughout the world, and more specifically
to the least developed countries and developing countries that
cannot afford insulin programs. By creating this affordable program
to bring solutions to those suffering from type 2 diabetes and its
complications to these countries and their people, Phoenix Life is
positioning itself to address the health and wellness of
millions of
diabetics worldwide.
To learn more about
Phoenix Life Sciences International, please visit https://phoenixlife.co/.
To
learn more about Phoenix Life's work in Vanuatu and how to register
for blood sugar screenings, please visit https://phoenixlife.vu.
###
About Phoenix
Life Sciences International Limited
Phoenix Life
Sciences International Limited is an adaptive healthcare solutions
company. Our business is to advance research and integrate programs
and manufacturing of products that target and treat diabetes, pain,
cancer, and address psychological, neurological, autoimmune and
sleep disorders. We strive to create partnerships and integrate
these programs for human health into communities worldwide as part
of our Global Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking
statements. These forward-looking statements involve, and are
subject to, known and unknown risks, uncertainties and other
factors which could cause the Company's actual results, performance
(financial or operating) or achievements to differ from the future
results, performance (financial or operating) or achievements
expressed or implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
All forward-looking statements attributable to the Companies herein
are expressly qualified in their entirety by the above-mentioned
cautionary statement. The Companies disclaim any obligation to
update forward-looking statements contained in this press release,
except as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements
have not been evaluated by the FDA and therefore the products sold
by Phoenix Life Sciences International are not available in the
U.S.
LEGAL
DISCLOSURE
Phoenix Life
Sciences International does not sell or distribute any products in
the United States that are in violation of the United States
Controlled Substances Act (US.CSA). This company does not grow,
sell, and distribute cannabis-based products in the United States
and is solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States where it is federally approved and in
compliance with the 1961 Single Convention on Narcotics.
Investor
Contact:
Phone:
1.888.717.5655 or international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW
Media
Kathryn@cmwmedia.com
619-972-3089